Skip to main content
Premium Trial:

Request an Annual Quote

Quest Commences Offer for Celera

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics today said that it has commenced its tender offer to acquire Celera for $8 per share.

The offer is being made through Quest's wholly owned subsidiary, Spark Acquisition Corp., and will expire on April 25 at 5:00 pm New York City time. The offer is subject to customary conditions, including the tender of a majority of Celera's outstanding shares and certain regulatory approvals.

Quest launched its acquisition offer nearly two weeks ago. The Madison, NJ-based lab giant would pay a total consideration of around $671 million, which includes $327 million in cash and short-term investments held by Celera.

Last week, the New Orleans Employees Retirement System filed a lawsuit against Celera, alleging its plan to sell the company to Quest for $671 million undervalues the company.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.